Johnson & Johnson (NYSE:JNJ) Receives Average Rating of “Moderate Buy” from Brokerages

Johnson & Johnson (NYSE:JNJ) has earned an average rating of “Moderate Buy” from the twenty-five brokerages that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, eighteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $265.3043.

Several research firms have commented on JNJ. The Goldman Sachs Group reiterated a “buy” rating and issued a $282.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. TD Cowen upped their price objective on Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Johnson Rice upgraded shares of Johnson & Johnson from an “outperform” rating to a “buy” rating and set a $280.00 price objective for the company in a report on Thursday, July 16th. Finally, Barclays boosted their target price on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 15th.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $255.71 on Thursday. The firm’s fifty day moving average price is $241.40 and its two-hundred day moving average price is $235.76. The stock has a market cap of $615.56 billion, a PE ratio of 29.63, a PEG ratio of 2.38 and a beta of 0.24. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a fifty-two week low of $164.23 and a fifty-two week high of $269.43.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. During the same period in the prior year, the company earned $2.77 EPS. Johnson & Johnson’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.68 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s payout ratio is 62.11%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA approved J&J’s OTTAVA robotic surgery system, opening the door for Johnson & Johnson to compete in robotic soft-tissue surgery and potentially expand its medtech growth runway. Reuters article on OTTAVA approval
• Positive Sentiment: Investors are also encouraged by the prospect of a phased launch of OTTAVA with select customers, suggesting J&J is preparing a commercial rollout after securing clearance. Medical Device Network article on OTTAVA launch plans
• Positive Sentiment: J&J also continues to look like a defensive income stock, with a newly declared quarterly dividend reinforcing its appeal to dividend-focused investors. Yahoo Finance dividend article
• Neutral Sentiment: A federal judge cast doubt on roughly 69,000 talc-related cancer claims, but the court did not dismiss the litigation outright, so the legal overhang remains a mixed but potentially improving risk for J&J. Reuters talc litigation article

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

A number of institutional investors have recently made changes to their positions in the stock. Greenberg Financial Group purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $954,000. World Investment Advisors boosted its holdings in shares of Johnson & Johnson by 19.6% in the 4th quarter. World Investment Advisors now owns 161,343 shares of the company’s stock worth $33,390,000 after purchasing an additional 26,450 shares in the last quarter. Coldstream Capital Management Inc. increased its position in shares of Johnson & Johnson by 9.8% during the 3rd quarter. Coldstream Capital Management Inc. now owns 95,662 shares of the company’s stock valued at $17,738,000 after purchasing an additional 8,533 shares during the last quarter. Benchmark Financial LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at about $554,000. Finally, Sagespring Wealth Partners LLC raised its holdings in shares of Johnson & Johnson by 6.2% during the 4th quarter. Sagespring Wealth Partners LLC now owns 45,222 shares of the company’s stock valued at $9,359,000 after buying an additional 2,660 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.